FAQ: Scinai Immunotherapeutics' First-Half 2025 Financial Results and Business Updates

What were Scinai Immunotherapeutics’ key financial results for the first half of 2025?

Scinai reported revenues of $773,000 for the six months ended June 30, 2025, up from $284,000 in the prior-year period, with net loss narrowing to $4.13 million compared to $4.48 million a year earlier.

How has Scinai strengthened its cash position recently?

As of June 30, 2025, cash and equivalents totaled $989,000, with an additional $4.2 million raised in July and August under the Company’s Standby Equity Purchase Agreement, significantly strengthening liquidity.

What progress has Scinai made in its therapeutic development programs?

Scinai advanced its anti-IL-17 NanoAb program and filed new patents under its Max Planck collaboration, while pursuing up to €27 million in grant funding to support clinical trials and pipeline development.

How is Scinai’s CDMO business performing?

The CDMO business showed continued growth, with $1.0 million in 2025 service orders booked through August, contributing to the revenue increase from $284,000 to $773,000 compared to the prior-year period.

What were the changes in Scinai’s operating expenses during this period?

R&D expenses fell to $1.24 million from $2.79 million, while marketing, general and administrative expenses rose to $1.26 million from $1.00 million compared to the prior-year period.

What are Scinai Immunotherapeutics’ two main business units?

Scinai has two complementary business units: one focused on in-house development of inflammation and immunology biological therapeutic products using VHH antibody fragments (nanoAbs), and the other a boutique CDMO providing biological drug development and manufacturing services.

Where can investors find more information about Scinai Immunotherapeutics?

The latest news and updates relating to SCNI are available in the company’s newsroom at https://ibn.fm/SCNI, and the full press release can be viewed at https://ibn.fm/cJ0J7.

What is the significance of Scinai’s reduced net loss and increased revenue?

The narrowed net loss to $4.13 million from $4.48 million and increased revenue demonstrate improved operational efficiency and growth in the CDMO business, indicating positive momentum in the company’s financial performance.